Literature DB >> 18383887

Expression of maspin in papillary Ta/T1 bladder neoplasms.

Stella Blandamura1, Emiliano D'Alessandro, Luciano Giacomelli, Vincenza Guzzardo, Wanni Battanello, Marcello Repele, Vito Ninfo.   

Abstract

BACKGROUND: The aim of the present study was to evaluate maspin expression in bladder urothelial papillary neoplasms and test the results for correlation with clinicopathological parameters. PATIENTS AND METHODS: A total of 111 urothelial neoplasms from 66 patients were evaluated: pathological examination of primary tumours disclosed 48 pTa and 18pT1. Fourteen additional biopsies, negative for neoplasm, were collected as control biopsies. For each of the 111 neoplastic samples and for the 14 control cases maspin and MIB1 immunoreactivity was evaluated. The immunohistochemical reactions of the 66 primary neoplasms were used for statistical analysis when the disease-free interval, presence and number of relapses, and progression of the disease were tested, whereas all of the 111 tumors were used when the association between the maspin pattern and histological grade and/or pT were evaluated. Thirty-three patients with primary pTa papillary neoplasms (68.7%) and 11 out of eighteen with pT1 (61%), had subsequent relapses of disease. For maspin immunoreactivity the presence/absence of nuclear staining and the pattern of staining were considered. Four patterns of reactivity were recognized and were used for statistical analyses.
RESULTS: A statistical association was found between the maspin pattern and pT, histological grade and nuclear staining.
CONCLUSION: In papillary urothelial neoplasms, maspin has a pattern of distribution that is associated with the histological grade and pathological stage, and this probably reflects its different activities in the neoplastic process.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18383887

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Maspin modulates adhesion of bladder carcinoma cells to vascular endothelium.

Authors:  Eva Juengel; Wolf-Dietrich C Beecken; Santhosh Mundiyanapurath; Tobias Engl; Dietger Jonas; Roman A Blaheta
Journal:  World J Urol       Date:  2010-03-25       Impact factor: 4.226

2.  Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer.

Authors:  Mario W Kramer; Sandra Waalkes; Jörg Hennenlotter; Jürgen Serth; Arnulf Stenzl; Markus A Kuczyk; Axel S Merseburger
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

3.  Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder Cancer.

Authors:  Johannes Breyer; Sanzhar Shalekenov; Atiqullah Aziz; Bastiaan W G van Rhijn; Johannes Bründl; Eva Lausenmeyer; Julius Schäfer; Stefan Denzinger; Christian Giedl; Maximilian Burger; Arndt Hartmann; Matthias Evert; Wolfgang Otto
Journal:  Bladder Cancer       Date:  2017-07-27

4.  Role of maspin in cancer.

Authors:  Rossana Berardi; Francesca Morgese; Azzurra Onofri; Paola Mazzanti; Mirco Pistelli; Zelmira Ballatore; Agnese Savini; Mariagrazia De Lisa; Miriam Caramanti; Silvia Rinaldi; Silvia Pagliaretta; Matteo Santoni; Chiara Pierantoni; Stefano Cascinu
Journal:  Clin Transl Med       Date:  2013-03-07

5.  Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.

Authors:  Jinbo Chen; Long Wang; Yunhua Tang; Guanghui Gong; Longfei Liu; Minfeng Chen; Zhi Chen; Yu Cui; Chao Li; Xu Cheng; Lin Qi; Xiongbing Zu
Journal:  J Exp Clin Cancer Res       Date:  2016-01-06

6.  Maspin is a PTEN-Upregulated and p53-Upregulated Tumor Suppressor Gene and Acts as an HDAC1 Inhibitor in Human Bladder Cancer.

Authors:  Yu-Hsiang Lin; Ke-Hung Tsui; Kang-Shuo Chang; Chen-Pang Hou; Tsui-Hsia Feng; Horng-Heng Juang
Journal:  Cancers (Basel)       Date:  2019-12-18       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.